Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study

被引:2
|
作者
Heron, Jack E. [1 ,2 ]
McManus, Hamish [3 ]
Vickers, Tobias [3 ]
Ryan, Kathleen [4 ,5 ]
Wright, Edwina [4 ,5 ,6 ]
Carter, Allison [3 ]
Stoove, Mark [5 ]
Asselin, Jason [5 ]
Grulich, Andrew [3 ]
Donovan, Basil [3 ]
Guy, Rebecca [3 ]
Varma, Rick [3 ,7 ]
Chen, Marcus [8 ,9 ]
Ryder, Nathan [3 ,10 ,11 ]
Lewis, David A. [12 ,13 ,14 ]
Templeton, David J. [15 ,16 ]
O'Connor, Catherine C. [3 ]
Gracey, David M. [1 ,15 ]
机构
[1] Royal Prince Alfred Hosp, Dept Renal Med, Camperdown, NSW, Australia
[2] Albury Wodonga Hlth, Dept Med, Wodonga, Vic, Australia
[3] Univ New South Wales, Kirby Inst, Kensington, NSW, Australia
[4] Alfred Hlth, Dept Infect Dis, Melbourne, Vic, Australia
[5] Burnet Inst, Melbourne, Vic, Australia
[6] Peter Doherty Inst, Melbourne, Vic, Australia
[7] Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW, Australia
[8] Melbourne Sexual Hlth Ctr, Alfred Hlth, Melbourne, Vic, Australia
[9] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[10] Hunter New England Clin, Tamworth, NSW, Australia
[11] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia
[12] Western Sydney Local Hlth Dist, Western Sydney Sexual Hlth Ctr, Parramatta, NSW, Australia
[13] Univ Sydney, Fac Med & Hlth, Westmead Clin Sch, Westmead, NSW, Australia
[14] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Westmead, NSW, Australia
[15] Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia
[16] Sydney Local Hlth Dist, Sexual Assault Med Serv, Dept Sexual Hlth Med, Sydney, NSW, Australia
来源
PLOS ONE | 2023年 / 18卷 / 02期
关键词
CHRONIC KIDNEY-DISEASE; DOUBLE-BLIND; INFECTION; MEN; PREVENTION; WOMEN;
D O I
10.1371/journal.pone.0280339
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
BackgroundTenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). Methods and findingsData were extracted from 52 sexual health clinics across Australia from 2009-2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to <60 ml/min/1 center dot 73m(2)) were calculated for people living with HIV (PLWHIV) prescribed TDF and HIV negative PrEP-users. Risk factors were assessed using Cox-proportional hazards models. Sensitivity analysis of risk using 1:1 propensity-score matching to adjust for potential imbalance in HIV and PrEP cohorts was conducted. 5,973 patients on PrEP and 1,973 PLWHIV were included. There were 39 (0.7%) instances of renal impairment in the PrEP group and 81 (4.1%) in the PLWHIV cohort (hazard ratio [HR]:0.35 95% confidence interval [CI]: 0.22-0.56). Rates of renal impairment were 4.01/1000 person-years (95%CI:2.93-5.48) in the PrEP cohort and 16.18/1000 person-years (95%CI:13.01-20.11) in the PLWHIV cohort (p<0.001). Predictors of renal impairment were: older age (40-49 years (HR:5.09 95%CI: 2.12-12.17) and 50-82 years (HR:13.69 95%CI: 5.92-31.67) (compared with 30-39 years) and baseline eGFR<90ml/min (HR:61.19 95%CI: 19.27-194.30). After adjusting for age and baseline eGFR the rate of renal impairment remained lower in the PrEP cohort (aHR:0.62 95%CI: 0.40-0.94, p = 0.023). In propensity-matched analysis using 1,622 patients per cohort the risk of renal impairment remained higher in the PLWHIV cohort (log-rank p = 0.001). ConclusionPatients prescribed TDF-based PrEP had lower rates of renal impairment than patients prescribed TDF for HIV infection. In propensity analysis, after matching for some risk factors, rates of renal impairment remained higher amongst patients with HIV.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Tenofovir disoproxil fumarate associated Fanconi syndrome in an HIV-uninfected man receiving HIV pre-exposure prophylaxis
    Dube, M. P.
    Funk, C. A.
    Corado, K.
    Morris, S.
    [J]. ANTIVIRAL THERAPY, 2016, 21 : A57 - A57
  • [2] Design and evaluation of mucoadhesive vaginal tablets of tenofovir disoproxil fumarate for pre-exposure prophylaxis of HIV
    Khan, Arshad Bashir
    Thakur, Ram Sharnagat
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2018, 44 (03) : 472 - 483
  • [3] Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention
    Mugwanya, Kenneth K.
    Baeten, Jared M.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (02) : 265 - 273
  • [4] Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report
    Zino, Leena
    Jacobs, Tom G.
    Nieuwenstein, Thomas
    Grintjes, Karin
    Colbers, Angela
    Burger, David M.
    [J]. AIDS, 2023, 37 (02) : 363 - 365
  • [5] Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
    Agbaji, Oche O.
    Abah, Isaac O.
    Ebonyi, Augustine O.
    Gimba, Zumnan M.
    Abene, Esla E.
    Gomerep, Simji S.
    Falang, Kakjing D.
    Anejo-Okopi, Joseph
    Agaba, Patricia A.
    Ugoagwu, Placid O.
    Agaba, Emmanuel I.
    Imade, Godwin E.
    Sagay, Atiene S.
    Okonkwo, Prosper
    Idoko, John A.
    Kanki, Phyllis J.
    [J]. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2019, 18
  • [6] Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study
    Molina, Jean-Michel
    Ghosn, Jade
    Assoumou, Lambert
    Delaugerre, Constance
    Algarte-Genin, Michele
    Pialoux, Gilles
    Katlama, Christine
    Slama, Laurence
    Liegeon, Geoffroy
    Beniguel, Lydie
    Ohayon, Michel
    Mouhim, Hanane
    Goldwirt, Lauriane
    Spire, Bruno
    Loze, Benedicte
    Surgers, Laure
    Pavie, Juliette
    Lourenco, Jeremy
    Ben-Mechlia, Mohamed
    Le Mestre, Soizic
    Rojas-Castro, Daniela
    Costagliola, Dominique
    [J]. LANCET HIV, 2022, 9 (08): : E554 - E562
  • [7] Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
    Hsiao, Yu-Yu
    Huang, Yi-Chia
    Chang, Sui-Yuan
    Kuo, Ching-Hua
    Chang, Shu-Fang
    Lin, Ya-Ting
    Luo, Yu-Zhen
    Lee, Yu-Lin
    Hung, Chien-Ching
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (04) : 755 - 757
  • [8] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Plosker, Greg L.
    [J]. DRUGS, 2013, 73 (03) : 279 - 291
  • [9] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    [J]. Drugs, 2013, 73 : 279 - 291
  • [10] Pre-exposure prophylaxis failure with tenofovir disoproxil
    Streeck, Hendrik
    Verheyen, Jens
    Storim, Julian
    Dittmer, Ulf
    Jochum, Christoph
    Timm, Jrg
    Esser, Stefan
    [J]. AIDS, 2017, 31 (01) : 176 - 177